

Lessons Learned from NIH Study About Long-term Outcomes of Patients with ARPKD/CHF

Meral Gunay-Aygun, MD

“Living with Childhood Polycystic Kidney Disease”
Children’s Hospital of Wisconsin


September 16, 2017



NIH Study

Since 2003
290 patients

(www.clinicaltrials.gov, NCT00068224)



NIH Study

(www.clinicaltrials.gov, NCT00068224)

- Aims
 - Define clinical and molecular characteristics
 - Identify correlations between gene mutations and clinical features
 - Identify outcome parameters for treatment trials
- Ages 6 months to 80 years
- 4-5 day evaluations at the NIH Clinical Center
 - Blood and urine tests for kidney, liver, and growth
 - MRI and Ultrasonography (USG) imaging
 - Cognitive evaluations
 - Sequencing of genes

Confirmation of Diagnosis

- 90 probable ARPKD patients evaluated
 - 78 patients (68 families) met clinical criteria
 - 73 patients (63 families) had *PKHD1* mutations
- Mutation detection rate 79 %
 - Kidney-predominant patients 82 %
 - Liver-predominant patients 63 %


PKHD1 Mutations

- 63 families (73 patients)
 - 43 families 2 mutations
 - 20 families 1 mutation
- Mutation types
 - Truncating (38 %)
 - Missense (62%)
- No patients with 2 truncating mutations

73 Molecularly Confirmed ARPKD Patients

- 29 males, 44 females
- Ages 1 to 56 y (14 ± 13 y)
 - 46 children
 - 17 adults
- 11 kidney transplantation before NIH visit
- 62 with native kidneys

Age at Diagnosis



	Perinatal (%) (Birth - 1 st month)	Non-perinatal (%) (After 1 st month)
n	48	52
Age at NIH evaluation	9 ± 7 y	17 ± 15 y


48 Perinatally Diagnosed ARPKD

- Oligohydramnios in 90 %
- Respiratory distress at birth in 70 %
 - 70 % mechanical ventilation
 - 37 % pneumothorax

Spectrum of Kidney Involvement in ARPKD

Medullary only


37 %



Corticomedullary


63 %

ARPKD: Ultrasound Classification




Ultrasound classification	Corticomedullary (%)	Medullary (%)
	63	37
Age at NIH evaluation	11 ± 12 y	14 ± 13 y


■ Corticomedullary □ Medullary




Kidney Volume




■ Corticomедullary ■ Medullary




Kidney Survival in ARPKD




Age at Transplantation




GFR





Pediatric



Adult



Hypertension




Liver Disease: Portal Hypertension

- Increased liver echogenicity in 92%
- Enlarged spleen in 65%
 - 60 % of children <5 y had enlarged spleen
 - Esophageal varices in 22 of 31 who had endoscopy
 - 5 had variceal bleeding at ages 5, 6, 32, 46, 50 y
 - Portosystemic shunt in 3 %
 - Liver transplantation in 1 %


Liver Disease: Bile Duct Abnormalities

- Bile duct abnormality in 70 %
 - Caroli syndrome in 40 %
 - Dilated common bile duct in 56 %
 - Enlarged gall bladder in 56 %
- Cholangitis in 6 %
 - 1 dilated common bile duct only
 - 3 completely normal imaging of bile system

ARPKD: Liver Function Preserved





Platelet Count and Portal Hypertension



Biliary System Involvement in ARPKD/CHF


20%



35 %




30 %



15 %

Kidney and Liver disease in ARPKD





Acknowledgements



Individuals with ARPKD and their families

**Medical College
of Wisconsin**
Ellis Avner
Bill Sweeney

NIDDK
Theo Heller

NHGRI
William A. Gahl
Joy Bryant
Jennifer Graf



NIMH
Joe Snow

NIH CC
Peter Choyke
Baris Turkbey
Kalish Daryanani

**NIH Clinical Center
Pediatric Inpatient
and Day Hospital**

NIH Children's Inn